3908
Z.-C. Song et al. / European Journal of Medicinal Chemistry 44 (2009) 3903–3908
4.3.2. General procedure for the preparation of TBTCA derivatives
10–18
(s, 4.5H); MS (ESI) m/z 402 (M-1). Anal. Calcd. for C15H18BrNO5S: C,
44.56; H, 4.49; N, 3.46. Found: C, 44.38; H, 4.47; N, 3.49.
A mixture of TCA (1.0 mmol) and appropriate NaOH (10%,
1.0 mmol) in dioxane (25 mL) was stirred at ice-water temperature
for 2 h. BOC2O (1.0 mmol) was added and stirred at ice-water
temperature for 1 h and then room temperature for 5 h. Most of the
solvent was extracted and appropriate amount of water was added
to adjust to neutral pH values. Ethyl acetate was added and extracted
(50 mL ꢂ 3), and washed with appropriate saturated aqueous solu-
tion of common salt, and dried with anhydrous magnesium
sulphate. Solvent was extracted to dry to obtain whiter solids 10–18.
4.3.2.8. (2RS,4R)-3-(tert-Butoxycarbonyl)-2-(3,5-dibromo-4-hydrox-
yphenyl)thiazolidine-4-carboxylic acid (17). Obtained as white
solids (0.429 g, 89%). 1H NMR (DMSO-d6)
d 7.38–7.51 (m, 2H), 5.72–
5.88 (m, 1H), 4.01–4.15 (m, 1H), 2.85–3.10 (m, 1H), 2.65–2.79 (m,
1H); 1.27 (s, 4.5H), 1.10 (s, 4.5H); MS (ESI) m/z 480 (M-1). Anal.
Calcd. for C15H17Br2NO5S: C, 37.29; H, 3.55; N, 2.90. Found: C, 37.02;
H, 3.57; N, 2.87.
4.3.2.9. (2RS,4R)-3-(tert-Butoxycarbonyl)-2-(3,5-di-tert-butyl-4-hy-
droxyphenyl)thiazolidine-4-carboxylic acid (18). Obtained as white
4.3.2.1. (2RS,4R)-3-(tert-Butoxycarbonyl)-2-phenylthiazolidine-4-
carboxylic acid (10). Obtained as white solids (0.283 g, 92%). 1H
solids (0.381 g, 87%). 1H NMR (DMSO-d6)
d 6.85–7.52 (m, 2H), 5.41–
NMR (DMSO-d6)
d
7.64–7.66 (m, 2H),
d
7.26–7.35 (m, 3H), 6.13 (s,
5.56 (m, 1H), 3.97–4.26 (m, 2H), 3.07–3.25 (m, 1H), 2.58–2.79 (m,
1H), 1.32 (s, 18H); 1.25 (s, 4.5H), 1.19 (s, 4.5H); MS (ESI) m/z 436 (M-
1). Anal. Calcd. for C23H35NO5S: C, 63.13; H, 8.06; N, 3.20. Found: C,
63.41; H, 8.04; N, 3.23.
0.5H), 5.97 (s, 0.5H), 4.73 (s, 0.5H), 4.59 (s, 0.5H), 3.44–3.50 (m, 1H),
2.09–2.21 (m, 1H), 1.35 (s, 4.5H), 1.12 (s, 4.5H); MS (ESI) m/z 308 (M-
1). Anal. Calcd. for C15H19NO4S: C, 58.23; H, 6.19; N, 4.53. Found: C,
58.05; H, 6.15; N, 4.57.
Acknowledgements
4.3.2.2. (2RS,4R)-3-(tert-Butoxycarbonyl)-2-(4-hydroxyphenyl)th-
iazolidine-4-carboxylic acid (11). Obtained as white solids (0.301 g,
The work was financed by grants (Project 30772627) from
National Natural Science Foundation of China.
86%). 1H NMR (DMSO-d6)
d 9.36 (s, 1H) 7.43 (d, 2H), 6.70 (d, 2H),
5.87–6.02 (m, 1H), 4.56–4.69 (m, 1H), 3.44 (dd, J ¼ 6.90 Hz, 6.90 Hz,
1H), 3.12–3.17 (m, 1H), 1.39 (s, 4.5H), 1.15 (s, 4.5H); MS (ESI) m/z 324
(M-1). Anal. Calcd. for C15H19NO5S: C, 55.37; H, 5.89; N, 4.30. Found:
C, 55.62; H, 6.85; N, 4.32.
References
[1] B. Jan, O. Barbara, K.M. Jan, O. Andrzej, Eur. J. Med. Chem. 42 (2007) 993–1003.
[2] V. Sriramurthy, G.A. Barcan, O. Kwon, J. Am. Chem. Soc. 129 (2007)
12928–12929.
[3] V. Gududuru, E. Hurh, J.T. Dalton, D.D. Miller, J. Med. Chem. 48 (2005)
2584–2588.
[4] B. Hartzoulakis, S. Rossiter, H. Gill, B. O’Hara, E. Steinke, P.J. Gane, R. Hurtado-
Guerrero, J.M. Leiper, P. Vallance, J.M. Rustc, D.L. Selwood, Bioorg. Med. Chem.
Lett. 17 (2007) 3953–3956.
[5] Y. Hiraiwa, T. Usui, Y. Akiyama, K. Maebashi, N. Minowa, D. Ikeda, Bioorg. Med.
Chem. Lett. 17 (2007) 3540–3543.
4.3.2.3. (2RS,4R)-3-(tert-Butoxycarbonyl)-2-(4-methoxyphenyl)th-
iazolidine-4-carboxylic acid (12). Obtained as white solids (0.324 g,
96%). 1H NMR (DMSO-d6)
d 7.54–7.57 (d, 2H), d 6.85–6.87 (d, 2H),
5.91–6.06 (m, 1H), 4.54–4.68 (m, 1H), 3.73 (s, 3H), 3.39–3.49 (m,
1H), 3.12–3.18 (m, 1H), 1.35 (s, 4.5H), 1.13 (s, 4.5H); MS (ESI) m/z 338
(M-1). Anal. Calcd. for C16H21NO5S: C, 56.62; H, 6.24; N, 4.13. Found:
C, 56.90; H, 6.21; N, 4.17.
[6] M. Tuncbilek, N. Altanlar, Arch. Pharm. Chem. Life Sci. 339 (2006) 213–216.
[7] J. Wrobel, J. Jetter, W. Kao, J. Rogers, L. Di, J. Chi, M.C. Perez, G.C. Chen, E.S. Shen,
´
Bioorg. Med. Chem. 14 (2006) 5729–5741.
[8] H.T. Nagasawa, D.J.W. Goon, R.T. Zera, D.L. Yuzon, J. Med. Chem. 25 (1982)
489–491.
[9] H.T. Nagasawa, D.J.W. Goon, W.P. Muldoon, R.T. Zera, J. Med. Chem. 27 (1984)
591–596.
4.3.2.4. (2RS,4R)-2-(4-Bromophenyl)-3-(tert-butoxycarbonyl)thia-
zolidine-4-carboxylic acid (13). Obtained as white solids (0.366 g,
95%). 1H NMR (DMSO-d6)
d 7.41–7.47 (m, 4H), 5.90–5.92 (m, 1H),
[10] M. Seki, Y. Mori, M. Hatsuda, S. Yamada, J. Org. Chem. 67 (2002) 5527–5536.
[11] A. Ei’ichi, N. Koichiro, S. Akihiko, N. Jeffrey-Tri, H. Koushi, H. Yoshio, N. Shingo,
K. Tooru, H. Yoshio, K. Yoshiaki, Bioorg. Med. Chem. Lett. 17 (2007) 4213–4217.
[12] N.A. Noureldin, J.W. Bellegarde, Synthesis 6 (1999) 943–946.
[13] H.D. Flack, Acta Crystallogr., Sect. A 39 (1983) 876–881.
[14] J. Zhang, S. Chen, T. Wu, P. Feng, X. Bu, J. Am. Chem. Soc. 130 (2008)
12882–12883.
[15] D.E. Williams, J. Davies, B.O. Patrick, H. Bottriell, T. Tarling, M. Roberge,
R.J. Andersen, Org. Lett. 10 (2008) 3501–3504.
[16] L. Shi, H.M. Ge, S.H. Tan, H.Q. Li, Y.C. Song, H.L. Zhu, Eur. J. Med. Chem. 42
(2007) 558–564.
4.90–4.92 (m, 1H), 3.31–3.37 (m, 2H), 1.25 (s, 9H); MS (ESI) m/z 338
(M-1). Anal. Calcd. for C15H18BrNO4S: C, 46.40; H, 4.67; N, 3.61.
Found: C, 46.72; H, 4.49; N, 3.66.
4.3.2.5. (2RS,4R)-3-(tert-Butoxycarbonyl)-2-(5-fluoro-2-hydroxyphe-
nyl)thiazolidine-4-carboxylic acid (14). Obtained as white solids
(0.319 g, 93%). 1H NMR (DMSO-d6)
d 9.83–9.87 (b, 1H), 7.75–7.79
(m, 1H), 6.85–6.92 (m, 1H), 6.73–6.77 (m, 1H), 6.09 (s,1H), 4.48–4.59
(m, 1H), 3.44 (dd, J ¼ 6.6 Hz, 6.3 Hz, 1H), 3.01–3.12 (m, 1H), 1.37
(s, 4.5H); 1.16 (s, 4.5H); MS (ESI) m/z 342 (M-1). Anal. Calcd. for
C15H18FNO5S: C, 52.47; H, 5.28; N, 4.08. Found: C, 52.11; H, 5.25;
N, 4.12.
[17] G. Turan-Zitouni, J.A. Fehrentz, P. Chevallet, J. Martinez, Z.A. Kaplancıklı,
¨
A. Ozdemir, M. Arslanyolu, M.T. Yıldız, Arch. Pharm. Chem. Life Sci. 340 (2007)
310–314.
[18] N.R. Pace, Science 276 (1997) 734–740.
[19] C.R. Woese, Microbiol. Rev. 51 (1987) 221–271.
[21] J.R. Govan, V. Deretic, Microbiol. Rev. 60 (1996) 539–574.
[22] A. Erik, Science 312 (2006) 1526–1530.
[23] T.L. Vincent, S.S. Roger, T. Burkhard, L. Stephen, Infect. Immun. 73 (2005)
1695–1705.
4.3.2.6. (2RS,4R)-3-(tert-Butoxycarbonyl)-2-(5-chloro-2-hydroxy-
phenyl)thiazolidine-4-carboxylic acid (15). Obtained as white solids
(0.312 g, 87%). 1H NMR (DMSO-d6)
d 10.11 (b, 1H), 7.96 (s, 1H), 7.12
[24] V. Mantareva, V. Kussovski, I. Angelov, E. Borisova, L. Avramov, G. Schnurpfeil,
D. Wo¨hrle, Bioorg. Med. Chem. 15 (2007) 4829–4835.
[25] T. Naito, S. Aburaki, H. Kamachi, Y. Narita, J. Okumura, H. Kawaguchi, J. Anti-
biot. 39 (1986) 1092–1107.
[26] A. Miyake, Y. Yoshimura, Y. Yamaoka, T. Nishimura, N. Hashimoto, A. Imada, J.
Antibiot. 45 (1992) 485–499.
(dd, J ¼ 2.7 Hz, 2.4 Hz,1H), 6.80 (s, 1H), 4.50–4.63 (m, 1H), 3.41–3.47
(m, 1H), 2.01–2.13 (m, 1H), 1.37 (s, 4.5H); 1.16 (s, 4.5H); MS (ESI) m/z
358 (M-1). Anal. Calcd. for C15H18ClNO5S: C, 50.07; H, 5.04; N, 3.89.
Found: C, 50.32; H, 5.01; N, 3.92.
[27] L. Verbist, J. Verhaegen, Antimicrob. Agents Chemother. 17 (1980) 807–812.
[28] C.H. O’callaghan, P. Acred, P.B. Harper, D.M. Ryan, S.M. Kirby, S.M. Harding,
Antimicrob. Agents Chemother. 17 (1980) 876–883.
[29] R. Wise, J.M. Andrews, L.J. Edwards, Antimicrob. Agents Chemother. 23 (1983)
559–564.
4.3.2.7. (2RS,4R)-2-(5-Bromo-2-hydroxyphenyl)-3-(tert-butoxycarbo-
nyl)thiazolidine-4-carboxylic acid (16). Obtained as white solids
(0.370 g, 92%). 1H NMR (DMSO-d6)
d 7.95–8.09 (m, 1H), 7.21 (dd,
J ¼ 2.70 Hz,2.40 Hz,1H), 6.70(s,1H), 6.02–6.05(m,1H), 4.46–4.54(m,
[30] G.M. Sheldrick, SHELXTL-97: Program for Crystal Structure Solution and
Refinement, University of Go¨ttingen, Go¨ttingen, Germany, 1997.
1H), 4.54 (s, 0.5H), 4.46 (s, 0.5H), 3.07–3.11 (m,1H),1.36 (s, 4.5H),1.13